跳至主要内容
临床试验/NCT05742724
NCT05742724进行中(未招募)1 期

The Pharmacokinetics of Oral Tetrahydrocannabinol and Cannabidiol Across the Spectrum of Glomerular Filtration Rate: a PharmacoKinetic Study

McMaster University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年1月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
24
试验地点
1
主要终点
Tetrahydrocannabinol and its metabolites renal clearance

研究概览

简要总结

POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.

详细描述

Adults aged greater than 25 years including 6 with eGFR>60ml/min/1.73m2, 6 eGFR 30-59ml/min/1.73m2, 6 eGFR <30ml/min/1.73m2 (CKD Epidemiology Collaboration equation) and 6 receiving in-center hemodialysis at least 2x weekly via a tunnelled catheter will receive THC 0.1mg/kg and CBD 2mg/kg by mouth in the form of MediPharm Labs-001 (MPL-001) (50mg CBD/2mg THC per 1mL). In healthy controls and participants with chronic kidney disease, blood samples will be collected at t=0, 1, 2, 3, 3.5 and 4 hours post THC/CBD administration. In participants receiving in-center hemodialysis, blood samples will be collected at t=0, 1, 2, 3, 3.5 and 4 hours post THC/CBD administration and during hemodialysis at t=0, 60, 120, 180 minutes and 15 minutes prior to the end of hemodialysis (at a reduced pump speed with blood flow 50-100ml/min) and 60 minutes post-hemodialysis. A 24 hour urine will be collected in all participants except those receiving hemodialysis without any residual urine output. Dialysate samples will be collected at 1,2,3 hours during hemodialysis and at the end of hemodialysis. Blood samples will also be collected at 24 and 48 hours. Plasma, urine and dialysis cannabinoids (THC, CBD and their metabolites) will be quantified using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
25 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adult age>25 years
  • estimated glomerular filtration rate (eGFR)>60ml/min/1.73m2 or eGFR<60ml/min/1.73m2 by the CKD Epidemiology Collaboration equation including in-center hemodialysis at least 2x weekly for a minimum of 3 hours per treatment via a tunnelled catheter treated >90 days
  • agree to take the medication as directed in the study
  • provides informed consent

排除标准

  • body mass index <20 or >35kg/m2
  • physical dependence on any drug other than caffeine or nicotine
  • history of clinically significant adverse event associated with cannabis intoxication
  • history of psychosis or mania or any active major psychiatric disorder
  • recent (within 30 days) use of any cannabinoid (natural or synthetic) identified by self-report or urine drug screen for cannabinoids
  • taking any medication with known interactions with THC or CBD via cytochrome P450 (CYP) CYP2C9, CYP2C19 and CYP4A6 or CYP2D4 (e.g. anti-epileptic drugs, calcineurin inhibitors, anti-fungal)
  • evidence of liver dysfunction (ALT less than 3 times upper limit of normal, bilirubin below upper limit of normal, international normalized ratio<1.5)
  • pregnant or breastfeeding women
  • change in ideal body weight or dry weight in the last 4 weeks
  • intradialytic hypotension (systolic blood pressure<90mmHg) requiring an intervention in the previous 4 weeks

研究组 & 干预措施

THC/CBD

Experimental

Oral THC 0.1mg/kg and CBD 2.5mg/kg

干预措施: Tetrahydrocannabinol-Cannabidiol Combination (Drug)

结局指标

主要结局

Tetrahydrocannabinol and its metabolites renal clearance

时间窗: 48 hours

Renal clearance

Tetrahydrocannabinol and its metabolites maximum concentration (Cmax)

时间窗: 48 hours

Maximum concentration (Cmax)

Cannabidiol and its metabolites maximum concentration (Cmax)

时间窗: 48 hours

Maximum concentration (Cmax)

Cannabidiol and its metabolites renal clearance

时间窗: 48 hours

Renal clearance

Tetrahydrocannabinol and its metabolites area under the curve

时间窗: 48 hours

Area under the curve

Cannabidiol and its metabolites dialytic clearance

时间窗: 48 hours

Dialytic clearance

Other cannabinoids and their metabolites last detection time

时间窗: 48 hours

Last detection time

Tetrahydrocannabinol and its metabolites time to Cmax

时间窗: 48 hours

Time to Cmax

Tetrahydrocannabinol and its metabolites last detection time

时间窗: 48 hours

Last detection time

Tetrahydrocannabinol and its metabolites dialytic clearance

时间窗: 48 hours

Dialytic clearance

Cannabidiol and its metabolites time to Cmax

时间窗: 48 hours

Time to Cmax

Cannabidiol and its metabolites last detection time

时间窗: 48 hours

Last detection time

Other cannabinoids and their metabolites maximum concentration (Cmax)

时间窗: 48 hours

Maximum concentration (Cmax)

Other cannabinoids and their metabolites area under the curve

时间窗: 48 hours

Area under the curve

Other cannabinoids and their metabolites renal clearance

时间窗: 48 hours

Renal clearance

Cannabidiol and its metabolites area under the curve

时间窗: 48 hours

Area under the curve

Other cannabinoids and their metabolites time to Cmax

时间窗: 48 hours

Time to Cmax

Other cannabinoids and their metabolites dialytic clearance

时间窗: 48 hours

Dialytic clearance

次要结局

  • Blood pressure(48 hours)
  • Heart rate(48 hours)
  • Adverse events(48 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验